Dossier assessment

Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A22-11
Last updated

Report documents

  1. Extract of dossier assessment

    Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 615 kB, EN, not accessible
  2. Dossier assessment

    Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 718 kB, DE, not accessible

Dossier assessment

Indication:

Treatment of X-linked hypophosphataemia (XLH) in patients aged 1 to 17 years with radiographic evidence of bone disease

Result of dossier assessment:
  • Children aged 1 to 12 years with an RSS total score ≥ 2.0: added benefit not proven.
  • Children aged 1 to 12 years with an RSS total score < 2.0: added benefit not proven.
  • Adolescents aged 13 to 17 years: added benefit not proven.

Project details

Project no.
A22-11
Commission
Commission awarded on 01.03.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Children's and adolescents' health
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G18-05
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)

    Project no.
    G19-15
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G20-27
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Burosumab (X-linked hypophosphataemia, = 18 years) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-12
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Burosumab (X-linked hypophosphataemia, 1 month to 1 year) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A26-74
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-88
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form